This was demonstrated in a preclinical study in murine prostate tumors in which delivery of PD-L1 blockade with concurrent EBRT did not delay tumor growth despite an increase in PD-L1 expression on tumors following EBRT [131]. The gene discussed is CD274; the disease is prostate neoplasm.